Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

The Pharmacokinetics of mRNA Vaccine Carrier using Carbon-14

  • Mi Hye Kwon (Korea Radio-Isotope Center for Pharmaceuticals, Korea Institute of Radiological and Medical Sciences) ;
  • Kwang Il Kim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences) ;
  • Yong Jin Lee (Korea Radio-Isotope Center for Pharmaceuticals, Korea Institute of Radiological and Medical Sciences) ;
  • Hye Kyung Chung (Korea Radio-Isotope Center for Pharmaceuticals, Korea Institute of Radiological and Medical Sciences)
  • Received : 2024.06.14
  • Accepted : 2024.06.21
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by the SARS-CoV-2 coronavirus, which had been identified in Wuhan, China, in December 2019. COVID-19 is a serious threat to human health and spread worldwide. World Health Organization (WHO) has declared the COVID-19 pandemic. It is important that vaccines and therapeutics are developed to control COVID-19. Among these, vaccines using COVID-19 mRNA platforms have various advantages, including a short development cycle, an easy industrialization, a simple production process, flexibility for new variants, and the capacity to induce better immune responses. This review summarizes the structure and characteristics of coronaviruses and introduces the use of non-clinical pharmacokinetic evaluation with C-14 in mRNA vaccine development. The in vitro stability of C-14 labeled mRNA carrier ([14C]mRNA carrier) was evaluated and found to be stable for up to 144 hours in rat serum. The [14C]mRNA carrier was distributed mostly to the administration site in rats, but slowly distributed to other organs after 48 hours. Most of the [14C]mRNA carrier remained in the administered muscle and was slowly excreted from the body through urine after 72 hours. There was no statistical difference in the distribution and excretion after intramuscular administration of the [14C]mRNA carrier to male and female rats. Through this paper, it is expected to contribute to the development of drug carriers through various studies using C-14.

Keywords

Acknowledgement

본 종설은 한국원자력의학원 연구운영지원사업(No.50539-2024)의 지원에 의하여 이루어졌으며 다른 이해관계는 없음을 밝힙니다.

References

  1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74. 
  2. Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol 2019;73:529-57. 
  3. Greenwood B. The contribution of vaccination to global health: Past, present and future. Philos Trans R Soc Lond Ser B Biol Sci 2014;369:20130433. 
  4. Badgujar KC, Ram AH, Zanznay R, Kadam H, Badgujar VC. Remdesivir for COVID-19: A review of pharmacology, mechanism of action, in-vitro activity and clinical use based on available case studies. Journal of Drug Delivery and Therapeutics 2020;10(4-S):264-70. 
  5. BadgujarKC, BadgujarAB, Patil VP, Dhangar DV. Hydroxychloroquine for COVID-19: a review and a debate based on available clinical trials/case studies. J Drug Deliv Theraupet 2020;10: 304-11. 
  6. Zhou J, Wang W, Zhong Q, Hou W, Yang Z, Xiao SY. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 2005;23:3202-9. 
  7. Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med 2018;50:110-20. 
  8. World Health Organization 2023 data.who.int; WHO Coronavirus (COVID-19) dashboard > Vaccines [Dashboard] 2023 Available from: https://data.who.int/dashboards/covid19/vaccines 
  9. Walter A Orenstein, Rafi Ahmed. Simply put: Vaccination saves lives. Proc Natl Acad Sci USA 2017;114(16):4031-3. 
  10. Matic Z, Santak M. Current view on novel vaccine technologies to combat human infectious diseases. Applied Microbiology and Biotechnology 2022;106(1):25-56. 
  11. Vaccine knowledge project, university of oxford, 2021.044. 
  12. Park KS, Sun X, Aikins ME, Moon JJ. Non-viral COVID-19 vaccine delivery systems. Advanced Drug Delivery Reviews 2020;169: 137-51. 
  13. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Molecular Therapy 2019;27(4):710-28. 
  14. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today 2019;28:100766. 
  15. Cherry JD, Krogstad P. SARS: the first pandemic of the 21st century. Pediatr Res 2004;56:1-5. 
  16. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery 2021;20(11):817-38. 
  17. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond, Vaccines (Basel), 2021.02.12 
  18. Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K. mRNA-based dendritic cell vaccines. Expert Rev Vaccines 2005;14(2):161-76. 
  19. Kranz LM. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016;534:396-401. 
  20. Sanche S, Lin YT, Xu C, Xu C, Severson ER, Hengartner N, Ke R. The novel coronavirus, 2019-nCoV is highly contagious and more infectious than initially estimated. medRxiv 2020;2002.03268. 
  21. Bahl, K. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 2017;25:1316-27. 
  22. Fscher, S.Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. Blood 2007;110:2457-65. 
  23. Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther 2017;24:133-43. 
  24. Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 2011;39(21):e142 
  25. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002;48:1647-53. 
  26. Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release 2016;240:227-34. 
  27. Petsch, B. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012;30:1210-16. 
  28. Malone RW, Felgner PL, Verma I M, Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci 1989;86:6077-81. 
  29. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17:261-79. 
  30. Dolgin E. The tangled history of mRNA vaccines. Nature 2021;597(7876):318-24. 
  31. Anand P, Stahel VP. The safety of Covid-19 mRNA vaccines: a review. Patient Safety in Surgery 2021;15:20. 
  32. Lappin G, Garner RC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem 2004;378(2):356-64. 
  33. Leonowens C, Pendry C, Bauman J. Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Br J Clin Pharmacol 2014;78(3):524-32. 
  34. Denton CL, Minthorn E, Carson SW. Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors. J Clin Pharmacol 2013;53(9):955-61.